{ "tag": [ "compiled" ], "id": "ocds-h6vhtk-068de0-2026-05-11T13:48:43+01:00", "date": "2026-05-11T13:48:43+01:00", "ocid": "ocds-h6vhtk-068de0", "initiationType": "tender", "parties": [ { "id": "GB-PPON-PBMQ-7576-DVGW", "name": "Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency", "identifier": { "scheme": "GB-PPON", "id": "PBMQ-7576-DVGW" }, "address": { "streetAddress": "10 South Colonnade", "locality": "London", "postalCode": "E14 4PU", "country": "GB", "countryName": "United Kingdom", "region": "UKI42" }, "contactPoint": { "name": "VMC Vaccines", "email": "vmc.vaccines@ukhsa.gov.uk" }, "roles": [ "buyer" ], "details": { "url": "https://www.gov.uk/government/organisations/uk-health-security-agency", "classifications": [ { "id": "publicAuthorityCentralGovernment", "scheme": "UK_CA_TYPE", "description": "Public authority - central government" } ] } } ], "buyer": { "id": "GB-PPON-PBMQ-7576-DVGW", "name": "Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency" }, "planning": { "milestones": [ { "id": "engagement", "type": "engagement", "description": "The UK Health Security Agency sent a short pre-market engagement questionnaire to known UK suppliers of tuberculosis intradermal skin tests to understand their capability to meet the requirements for the intradermal diagnostic skin test for the detection of Mycobacterium tuberculosis infection. Insights collected primarily focused on product specification, shelf life and supply chain to better understand the current market landscape.", "dateMet": "2026-03-13T00:00:00Z", "status": "met" } ], "documents": [ { "id": "039130-2026", "documentType": "marketEngagementNotice", "noticeType": "UK2", "description": "Preliminary market engagement notice on Find a Tender", "url": "https://www.find-tender.service.gov.uk/Notice/039130-2026", "datePublished": "2026-04-29T12:21:11+01:00", "format": "text/html" } ] }, "tender": { "id": "C426981", "legalBasis": { "id": "2023/54", "scheme": "UKPGA", "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents" }, "title": "BCG Vaccine & TB Skin Test (2027)", "description": "The provision of Bacillus Calmette-Guerin (BCG) vaccine and intradermal diagnostic skin test for the detection of Mycobacterium tuberculosis infection. Deliveries will be required up to a period of 2 years, with an option to extend for up to an additional 24 months. Information about volumes for each lot is included in the Invitation to Offer documents.", "items": [ { "id": "1", "additionalClassifications": [ { "scheme": "CPV", "id": "33651600", "description": "Vaccines" } ], "deliveryAddresses": [ { "region": "UK", "country": "GB", "countryName": "United Kingdom" }, { "region": "UK", "country": "GB", "countryName": "United Kingdom" } ], "relatedLot": "1" }, { "id": "2", "additionalClassifications": [ { "scheme": "CPV", "id": "33694000", "description": "Diagnostic agents" } ], "deliveryAddresses": [ { "region": "UK", "country": "GB", "countryName": "United Kingdom" } ], "relatedLot": "2" } ], "value": { "amountGross": 0, "amount": 0, "currency": "GBP" }, "mainProcurementCategory": "goods", "aboveThreshold": true, "lots": [ { "id": "1", "contractPeriod": { "startDate": "2027-04-01T00:00:00+01:00", "endDate": "2029-03-31T23:59:59+01:00", "maxExtentDate": "2031-03-31T23:59:59+01:00" }, "hasRenewal": true, "status": "active", "title": "Bacillus Calmette-Guerin (BCG) vaccine", "description": "BCG vaccine indicated for the prevention of Tuberculosis", "value": { "amountGross": 0, "amount": 0, "currency": "GBP" }, "awardCriteria": { "weightingDescription": "Full details of the award criteria can be found in the tender documentation.", "criteria": [ { "type": "quality", "name": "Quality criterion", "description": "Comparison with specification" }, { "type": "quality", "name": "Quality criterion", "description": "Risk to programme delivery" }, { "type": "quality", "name": "Quality criterion", "description": "Social value" }, { "type": "cost", "name": "Cost criterion", "description": "Benchmark price" }, { "type": "cost", "name": "Cost criterion", "description": "Product price" }, { "type": "cost", "name": "Cost criterion", "description": "Additional costs" }, { "type": "cost", "name": "Cost criterion", "description": "Storage costs" }, { "type": "quality", "name": "Quality critierion", "description": "Comparison with specification" }, { "type": "quality", "name": "Quality criterion", "description": "Risk to programme delivery" }, { "type": "quality", "name": "Quality criterion", "description": "Social value" }, { "type": "cost", "name": "Cost criterion", "description": "Benchmark price" }, { "type": "cost", "name": "Cost criterion", "description": "Product price" }, { "type": "cost", "name": "Cost criterion", "description": "Additional costs" }, { "type": "cost", "name": "Cost criterion", "description": "Storage costs" } ] }, "renewal": { "description": "There is an option for the Authority to extend for a period or periods up to an additional 24 months" } }, { "id": "2", "title": "Intradermal diagnostic skin test for the detection of Mycobacterium tuberculosis", "description": "An intradermal diagnostic skin test, indicated for the detection of Mycobacterium tuberculosis infection", "status": "active", "value": { "amountGross": 0, "amount": 0, "currency": "GBP" }, "awardCriteria": { "weightingDescription": "Full details of the award criteria can be found in the tender documentation.", "criteria": [ { "type": "quality", "name": "Quality criterion", "description": "Comparison with specification" }, { "type": "quality", "name": "Quality criterion", "description": "Risk to programme delivery" }, { "type": "quality", "name": "Quality criterion", "description": "Social value" }, { "type": "cost", "name": "Cost criterion", "description": "Benchmark price" }, { "type": "cost", "name": "Cost criterion", "description": "Product price" }, { "type": "cost", "name": "Cost criterion", "description": "Additional costs" }, { "type": "cost", "name": "Cost criterion", "description": "Storage costs" }, { "type": "quality", "name": "Quality critierion", "description": "Comparison with specification" }, { "type": "quality", "name": "Quality criterion", "description": "Risk to programme delivery" }, { "type": "quality", "name": "Quality criterion", "description": "Social value" }, { "type": "cost", "name": "Cost criterion", "description": "Benchmark price" }, { "type": "cost", "name": "Cost criterion", "description": "Product price" }, { "type": "cost", "name": "Cost criterion", "description": "Additional costs" }, { "type": "cost", "name": "Cost criterion", "description": "Storage costs" } ] }, "contractPeriod": { "startDate": "2027-04-01T00:00:00+01:00", "endDate": "2029-03-31T23:59:59+01:00", "maxExtentDate": "2031-03-31T23:59:59+01:00" }, "hasRenewal": true, "renewal": { "description": "There is an option for the Authority to extend for a period or periods up to an additional 24 months" } } ], "communication": { "futureNoticeDate": "2026-05-06T23:59:59+01:00" }, "status": "active", "procurementMethod": "open", "procurementMethodDetails": "Competitive flexible procedure", "procedure": { "features": "This procurement is conducted in accordance with the Procurement Act 2023 using a competitive flexible procedure. Initial Offers will be evaluated by the Authority against the award criteria set out in the Invitation to Offer. * Lot 1: Offerors for Lot 1 who pass the award criteria will proceed to the negotiation stage if a negotiation stage is required. A negotiation stage will be used for Lot 1 if any elements of the Offer are unclear or do not meet the Specification or otherwise require discussion using the subjects for negotiation set out * Lot 2: Offerors who pass the award criteria outlined will proceed to the negotiation stage for Lot 2. The Authority may choose to negotiate different aspects of the Offers with different Offerors, provided that the Authority does so in a manner consistent with the principles set out in section 12 of the Procurement Act 2023, including the duty to act transparently and to treat suppliers fairly. After the Negotiation Stage has closed, the Authority will invite final Offers in the form of a resubmission. Further information on the negotiation process is described in the tender documentation." }, "submissionMethodDetails": "https://health-family.force.com/s/Welcome", "submissionTerms": { "electronicSubmissionPolicy": "allowed", "languages": [ "en" ] }, "tenderPeriod": { "endDate": "2026-06-15T13:00:00+01:00" }, "enquiryPeriod": { "endDate": "2026-06-01T13:00:00+01:00" }, "awardPeriod": { "endDate": "2026-10-20T23:59:59+01:00" }, "documents": [ { "id": "conflictOfInterest", "documentType": "conflictOfInterest" }, { "id": "043013-2026", "documentType": "tenderNotice", "noticeType": "UK4", "description": "Tender notice on Find a Tender", "url": "https://www.find-tender.service.gov.uk/Notice/043013-2026", "datePublished": "2026-05-11T13:48:43+01:00", "format": "text/html" } ], "hasRecurrence": true, "recurrence": { "dates": [ { "startDate": "2026-10-20T23:59:59+01:00" } ] }, "riskDetails": "The below known unknown risks has been identified, which may require modification of the contract under paragraph 5 of Schedule 8 to the PA 2023 if one of the below identified risks materialise. Risk 1: The COVID-19 pandemic led to lockdown events, which disrupted the distribution and uptake of some national immunisation campaigns. The forecast delivery and stock requirements were substantially changed as a result. An ongoing risk is the materialisation of a UK health emergency or global pandemic, which may materialise in any given year. How the risk may impact on the performance of the contract: A health emergency or pandemic may materially affect the uptake of the product(s). Continued delivery of the product(s) within the original term of the contract could jeopardise stock management and effective use of product before expiry. Why is it not possible to address the potential impact of such risks? UKHSA and suppliers cannot reasonably predict the occurrence of a pandemic. UKHSA cannot determine an effective delivery schedule and contract term which would be effective during a pandemic to mitigate the risk of reduced uptake." }, "language": "en" }